Protocol Ledger

NCT04844866 · Phase II · RECRUITING

Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients

Interventional Phase II clinical trial protocol NCT04844866 sponsored by Miltenyi Biomedicine in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-08-18 Enrollment: 213 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT04844866
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)213 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04844866
Protocol FieldVerified Registry Value
NCT IdentifierNCT04844866
Consolidated Lead SponsorMiltenyi Biomedicine
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment213 participants (ESTIMATED)
Registered Start Date2021-08-18
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT04844866
Hospital Research SiteLocationSite Profile
Turku University HospitalTurku, FinlandOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI